Feb 6, 2024 · OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein. Here we present results from a phase 1 study of OMO-103 in advanced solid tumors, established to …

Oct 28, 2019 · Taken together, our data suggest that the mechanism of action of Omomyc is to bind DNA as either a homodimer or a heterodimer with Max that is formed cotranslationally, …

Omomyc treatment appears to rebalance the Myc/Max ratio by binding both Myc and Max proteins and preventing their interaction. Omomyc can function like Mad1, where it …

Nov 11, 2022 · Omomyc — a cell-penetrating peptide now renamed OMO-103 — appears safe and potentially effective in humans, they reported at the EORTC-NCI-AACR triple meeting in …

Omomyc mini-protein is a dominant-negative form of MYC that is used to inhibit MYC for research purposes but was thought to be too unwieldy for in vivo therapy. However, Beaulieu et al. …

Omomyc forms heterodimers with MYC that are not able to bind DNA, but also homodimers and heterodimers with MAX that, instead, occupy DNA as inactive protein complexes, shutting …

Oct 17, 2016 · OmoMYC attenuates both MYC-dependent activation and repression by competing with MYC/MAX for binding to chromatin, effectively lowering MYC/MAX occupancy at its …

Omomyc selectively targets Myc protein interactions: it binds c- and N-Myc, Max and Miz-1, but does not bind Mad or select HLH proteins. Specifically, it prevents Myc binding to promoter E …

Apr 4, 2020 · The recently described therapeutic effect of purified Omomyc mini-protein-following the surprising discovery of its cell-penetrating capacity-constitutes a paradigm shift. Now, …

Oct 26, 2022 · Developed in-house by Laura Soucek’s Models of Cancer Therapies Group and VHIO-ICREA spin-off Peptomyc SL, OMO-103 targets the MYC oncogene which is …